Compare Enveric Biosciences Inc (ENVB) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Southwest Airlines Co — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Southwest Airlines Co trades at $41.4 (market cap $20.41B). The key difference: Southwest Airlines Co is far larger — about 3050.8× Enveric Biosciences Inc's market cap, and Southwest Airlines Co pays a 1.73% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Southwest Airlines Co for 65 Days on average.
| ENVB | LUV | |
|---|---|---|
Market Cap | $6.69M | $20.41B |
Volume | 41,141 | 4,706,365 |
Sector | Health | Industrials |
52-Week High | $10.80 | $54.80 |
52-Week Low | $1.27 | $29.67 |
Typical Hold Time | 14 Days | 65 Days |
Enterprise Value | -$1.60M | $23.51B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Southwest Airlines (LUV) trades at $41.36, down 2.57% with a bearish technical signal. The company shows mixed fundamentals with a P/E of 26.08 and net margin of 2.78%, while recent earnings beat expectations in Q2 2026. Cash flow trends improved significantly in 2026 projections. Analyst consensus is divided with 42% buy ratings and a $49.61 price target representing 20% upside potential.
LUV's transformation initiatives show promise with projected $2 billion EBIT from new fare structures, though high fuel costs and competitive pressures remain risks. The stock offers value with P/S of 0.73 and strong revenue growth outlook, but requires monitoring of Q3 2026 earnings due October 22 for confirmation of the turnaround trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
